Stelara 90 Mg Every Four Weeks denials in California external review
In the California DMHC record, independent physician reviewers decided 12 published external-review cases involving Stelara 90 Mg Every Four Weeksand overturned the plan’s denial in 100%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Stelara 90 Mg Every Four Weeks denials
| Category | Decisions | Overturned |
|---|---|---|
| Crohn's Disease | 9 | 100% |
| Ulcerative Colitis | 3 | 100% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Stelara (ustekinumab) 90 mg from every four weeks. Current medical literature supports dose escalation of Stelara to 90 mg every four weeks in this case. Sands and colleagues report in a double-blind, placebo-controlled trial of ustekinumab as induction and maintenance therapy for ulcerative colitis that a single intravenous dose of Stelara induced clinical remission in a significantly greater proportion of patients than placebo did, as measured by both clinical response and endoscopic response. Kopylov and colleagues note that dosing at 90 mg every four weeks was used frequently to address inadequate disease control, and a large proportion of patients were able to maintain response with dose escalation to 90 mg every four weeks.
Nature of Statutory Criteria/Case Summary: The patient has been diagnosed with Crohn’s disease. The provider noted that the patient had been treated with Remicade, Humira, Cimzia, Entyvio, and azathioprine. The provider noted the patient was status post small bowel resections and had failed treatment with Entyvio and Stelara 90 mg every eight weeks. The provider noted that the patient was taking Stelara 90 mg every four weeks. The patient reported that her symptoms, including diarrhea, had significantly improved. The patient has requested authorization and coverage for Stelara 90 mg every four weeks. The Health Plan denied the request and reported the requested medication regimen is not medically necessary for the treatment of this patient. At issue in this case is whether Stelara 90 mg every four weeks is medically necessary for the treatment of the patient’s medical condition.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Stelara — and what reviewed cases show
This page covers the Stelara auto-injector dosage form, which the source data counts separately. The medication, the denial patterns, and the appeal strategy are the same — see the full Stelara record here.
Stelara (ustekinumab) is FDA-approved for: crohn's disease (adults); ulcerative colitis (adults); plaque psoriasis and psoriatic arthritis. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Biosimilar and formulary switching
Ustekinumab biosimilars — including an FDA-designated interchangeable — are now on formularies, and plans are moving patients off brand Stelara. If you're stable, the exception question is whether a switch risks your remission; if you're starting fresh, expect the plan to steer to its preferred product.
Dose-interval escalation denied
Gastroenterologists sometimes shorten Stelara's maintenance interval when disease activity returns before the next scheduled dose. Plans deny the extra doses as exceeding quantity limits. This is a prescriber-judgment fight: response history and drug-level or inflammatory-marker documentation carry it.
Step therapy behind TNF blockers
Formularies frequently require TNF-blocker failure before an IL-12/23 agent. Documented prior biologic history — or the clinical reasons a TNF blocker is wrong for you — is the standard exception ground.
Both step-therapy and quantity-limit denials route through the formulary exception process: the prescriber's supporting statement about your prior treatment and clinical needs triggers short mandatory decision deadlines.
Evidence cited in overturned Stelara decisions
- Document the full biologic history: what was tried, how long, and why it stopped working or couldn't be used.
- For interval-escalation denials, have the prescriber connect the requested regimen to your documented disease activity — this is dosing judgment, not experimental use of the drug.
- If the plan is forcing a switch mid-remission, make the risk of relapse the centerpiece and demand the clinical basis for interrupting stable therapy.
- Request the exact criteria and the reviewer's specialty; IBD dosing decisions reviewed without gastroenterology input are challengeable on that basis.
The published California record contains 12 external-review decisions involving Stelara; 100% were overturned. This historical rate does not predict another case. For the full class-wide picture — step therapy, biosimilar switching, dose caps, and the record for every IBD biologic — see the Crohn’s & colitis biologic appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Stelara 90 Mg Every Four Weeks, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY